Omnicell, Inc. (NASDAQ:OMCL) Receives $59.86 Average Target Price from Analysts

Omnicell, Inc. (NASDAQ:OMCL) has been assigned a consensus recommendation of “Buy” from the nine ratings firms that are currently covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among brokers that have covered the stock in the last year is $59.8571.

A number of analysts have commented on OMCL shares. UBS Group set a $60.00 price objective on Omnicell and gave the stock a “buy” rating in a research report on Friday, March 13th. Benchmark restated a “buy” rating on shares of Omnicell in a research report on Friday, March 13th. Weiss Ratings upgraded Omnicell from a “sell (d)” rating to a “hold (c-)” rating in a research report on Thursday, May 7th. Bank of America upgraded Omnicell from a “neutral” rating to a “buy” rating and set a $70.00 target price for the company in a research report on Wednesday, February 4th. Finally, KeyCorp raised their target price on Omnicell from $60.00 to $70.00 and gave the stock an “overweight” rating in a research report on Tuesday, April 28th.

Key Stories Impacting Omnicell

Here are the key news stories impacting Omnicell this week:

• Positive Sentiment: Craig-Hallum raised its price target on Omnicell to $55 from $53 and reiterated a Buy rating after the company’s Q1 update, reinforcing a constructive view on the shares. Here is What Analysts Are Saying About Omnicell, Inc. (OMCL)
• Positive Sentiment: Zacks Research boosted its earnings estimates for multiple periods, including FY2026 to $1.27 per share from $0.87, FY2027 to $1.34 from $1.13, and FY2028 to $1.71 from $1.44, suggesting improving long-term profitability. Here is What Analysts Are Saying About Omnicell, Inc. (OMCL)
• Positive Sentiment: Zacks also increased near-term quarterly EPS forecasts across 2026 and 2027, including Q2 2026 to $0.30 from $0.19 and Q4 2027 to $0.37 from $0.30, while maintaining a Strong-Buy rating, which may support investor confidence. Here is What Analysts Are Saying About Omnicell, Inc. (OMCL)
• Neutral Sentiment: Other analyst notes summarized the broader post-earnings reaction, with multiple firms revising their models after Omnicell’s Q1 2026 beat, adding to the stock’s momentum but not introducing new company-specific catalysts. Here is What Analysts Are Saying About Omnicell, Inc. (OMCL)

Insider Activity at Omnicell

In related news, EVP Corey J. Manley sold 7,405 shares of the firm’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $34.69, for a total transaction of $256,879.45. Following the completion of the transaction, the executive vice president owned 96,717 shares in the company, valued at $3,355,112.73. This trade represents a 7.11% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 2.92% of the stock is owned by company insiders.

Hedge Funds Weigh In On Omnicell

Several institutional investors have recently bought and sold shares of OMCL. Wellington Management Group LLP raised its position in Omnicell by 156.4% in the 4th quarter. Wellington Management Group LLP now owns 2,075,362 shares of the company’s stock valued at $94,014,000 after purchasing an additional 1,265,818 shares during the last quarter. Millennium Management LLC bought a new position in Omnicell in the 3rd quarter valued at $25,625,000. First Light Asset Management LLC bought a new position in Omnicell in the 1st quarter valued at $16,351,000. Boston Partners bought a new position in Omnicell in the 4th quarter valued at $20,805,000. Finally, WCM Investment Management LLC bought a new position in Omnicell in the 1st quarter valued at $9,783,000. Institutional investors own 97.70% of the company’s stock.

Omnicell Price Performance

Shares of OMCL stock opened at $43.12 on Wednesday. The stock has a 50 day moving average of $37.64 and a two-hundred day moving average of $40.41. The company has a current ratio of 1.50, a quick ratio of 1.29 and a debt-to-equity ratio of 0.13. Omnicell has a 12 month low of $26.84 and a 12 month high of $55.00. The company has a market capitalization of $1.96 billion, a P/E ratio of 98.00, a P/E/G ratio of 1.12 and a beta of 0.96.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings data on Tuesday, April 28th. The company reported $0.55 EPS for the quarter, topping analysts’ consensus estimates of $0.33 by $0.22. Omnicell had a return on equity of 4.00% and a net margin of 1.67%.The company had revenue of $309.88 million during the quarter, compared to the consensus estimate of $304.02 million. During the same quarter last year, the company earned $0.26 EPS. The company’s quarterly revenue was up 14.9% on a year-over-year basis. Omnicell has set its FY 2026 guidance at 1.800-2.000 EPS and its Q2 2026 guidance at 0.400-48.000 EPS. As a group, equities analysts expect that Omnicell will post 1.31 EPS for the current year.

Omnicell Company Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.